Tofogliflozin - Chugai Pharmaceutical
Alternative Names: Apleway; CSG452; Deberza; R 7201; RG 7201; RO4998452; Tofogliflozin hydrateLatest Information Update: 05 Nov 2023
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Kowa; Osaka University School of Medicine; Sanofi K.K.
- Class Antihyperglycaemics; Benzhydryl compounds; Benzofurans; Cardiovascular therapies; Glucosides; Hepatoprotectants; Small molecules; Spiro compounds; Vascular disorder therapies
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase II Non-alcoholic steatohepatitis
- Discontinued Atherosclerosis
Most Recent Events
- 14 Apr 2022 Phase-II clinical trials in Non-alcoholic steatohepatitis (Combination therapy) in USA (PO) (NCT05327127)
- 07 Sep 2021 Discontinued - Phase-II for Atherosclerosis in Japan (PO)
- 07 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus (Adjunctive treatment, Treatment-experienced) in Japan (PO)